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Changes  in  the  abundance  and  post-translational  modiﬁcation  of  proteins  and  accumulation  of  some
covalently  modiﬁed  proteins  have  been  proposed  to  represent  hallmarks  of  biological  ageing.  Within  the
frame  of the  Mark-Age  project,  the  workpackage  dedicated  to  “markers  based  on  proteins  and  their  mod-
iﬁcations”  has  been  ﬁrstly  focused  on  enzymatic  and  non-enzymatic  post-translational  modiﬁcations  ofiomarkers
rotein modiﬁcation
rotein maintenance
serum  proteins  by carbohydrates.  The  second  focus  of the  workpackage  has  been  directed  towards  protein
maintenance  systems  that  are involved  either  in  protein  quality  control  (ApoJ/Clusterin)  or in  the  removal
of  oxidatively  damaged  proteins  through  degradation  and  repair  (proteasome  and  methionine  sulfoxide
reductase  systems).  This  review  describes  the  most  relevant  features  of these  protein  modiﬁcations  and
maintenance  systems,  their  fate during  ageing  and/or  their implication  in  ageing  and  longevity.
© 2015  The  Authors.  Published  by Elsevier  Ireland  Ltd.  This  is an open  access  article  under  the CC. Introduction
Changes in the abundance and post-translational modiﬁca-
ion of proteins and accumulation of some covalently modiﬁed
roteins have been proposed to represent hallmarks of biologi-
al ageing (Friguet, 2002; Stadtman, 2006; Chondrogianni et al.,
014a). Within the frame of the Mark-Age project, the workpackage
Abbreviations: AGEs, advanced glycation endproducts; ApoJ/CLU, Apolipopro-
ein J/Clusterin; ROS, reactive oxygen species; PBMC, peripheral blood mononuclear
ells; Msr, methionine sulfoxide reductase; GalNAc, N-acetylgalactosamine; Glc-
Ac,  N-acetylglucosamine; ER, endoplasmic reticulum; Ig, Immunoglobulins; MGO,
ethylglyoxal; GO, Glyoxal; 3-DG, deoxyglucosone; MRP, Maillard reaction prod-
cts; CML, carboxymethyllysine; RAGE, receptor for advanced glycation end
roducts; HMGB1, high mobility group box 1 protein; LPS, lipopolysaccharide;
C-MS/MS, liquid chromatography–mass spectrometry with tandem mass spec-
rometry; AF, autoﬂuorescence; HDL, high-density lipoprotein; PA, proteasome
ctivator.
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256, Biological adaptation and ageing – IBPS, F-75005 Paris, France.
el.: +33 1 44 27 37 02; fax: +33 1 44 27 51 40.
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047-6374/© 2015 The Authors. Published by Elsevier Ireland Ltd. This is an open
icenses/by-nc-nd/4.0/).BY-NC-ND  license  (http://creativecommons.org/licenses/by-nc-nd/4.0/).
dedicated to “markers based on proteins and their modiﬁcations”
has been ﬁrstly focused on enzymatic and non-enzymatic post-
translational modiﬁcations of serum proteins by carbohydrates.
Indeed, one important physiological post-translational modiﬁca-
tion of secreted proteins is addition of N-linked oligosaccharides
(N-glycans). Since most N-glycans are on the outer surface of cel-
lular and secreted macromolecules, they can modulate or mediate
a wide variety of events in cell–cell and cell-matrix interactions
crucial for the development and function of complex multicellular
organisms (Ohtsubo and Marth, 2006). Because the biosynthesis
of glycans is not controlled by interaction with a template but
depends on the complicated concerted action of glycosyltrans-
ferases, the structures of glycans are much more variable than
those of proteins and nucleic acids, and they can be easily altered
by the physiological conditions of the cells. Accordingly, study-
ing age-related alterations of the glycans could be relevant to
understanding the complex physiological changes in ageing indi-
viduals (Dall’Olio et al., 2013). Non-enzymatic protein glycation is a
common post-translational modiﬁcation of proteins in vivo, result-
ing from reactions between glucose or its metabolites and amino
groups on proteins, this process is termed “Maillard reaction” and
 access article under the CC BY-NC-ND license (http://creativecommons.org/
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eads to the formation of advanced glycation end products (AGEs)
Vlassara et al., 1984). During normal ageing, there is accumulation
f AGEs on long-lived proteins such as collagens and several car-
ilage proteins. AGEs, either directly or through interactions with
heir receptors, are involved in the pathophysiology of numerous
ge-related diseases, such as cardiovascular and renal diseases and
eurodegeneration (Sell and Monnier, 2012; Li et al., 2012; Simm,
013).
The second focus of the workpackage has been directed towards
rotein maintenance systems that are involved either in protein
uality control or in the removal of oxidatively damaged pro-
eins through degradation and repair (Friguet, 2006; Breusing and
rune, 2008; Baraibar and Friguet, 2012; Chondrogianni et al.,
014a). Hence, the highly conserved multifunctional glycoprotein,
polipoprotein J/Clusterin (ApoJ/CLU) has been analysed since,
mong its several physiological functions, this protein is a chap-
rone that stabilizes stressed proteins in a folding-competent state
Poon et al., 2000; Narayan et al., 2012). Moreover, previous work
as shown that ApoJ/CLU is associated with human ageing and
ith ageing of human cells in vitro, and that its serum level is
ncreased in patients with type II diabetes, coronary heart disease,
nd myocardial infarction (Trougakos and Gonos, 2006). There-
ore ApoJ/CLU may  represent a valuable ageing biomarker. Beside
rotein glycation, it is also well known that levels of oxidised pro-
eins increase with age, due to increased protein damage induced
y reactive oxygen species (ROS), decreased elimination of oxi-
ized protein (i.e.  repair and degradation), or a combination of both
Chondrogianni et al., 2014a). Since the proteasome is in charge
f both general protein turnover and removal of oxidized pro-
ein, its fate during ageing has received considerable attention,
nd evidence has been provided for impairment of the protea-
ome function with age in different cellular systems, including
uman peripheral blood mononuclear cells (PBMC) (Friguet, 2006;
reusing and Grune, 2008; Baraibar and Friguet, 2012). In addi-
ion to being degraded, certain oxidised proteins can be repaired.
owever, repair is limited to the reversion of a few oxidative mod-
ﬁcations of sulfur-containing amino acids, such as the reduction
f methionine sulfoxide by the methionine sulfoxide reductase
Msr) system (Moskovitz, 2005). Evidence has been provided that
sr  activity is impaired during ageing and replicative senescence
Petropoulos and Friguet, 2006). Thus, these protein mainte-
ance systems may  also be viewed as potential biomarkers of
geing.
This review article summarizes the most important features of
he above mentioned protein modiﬁcations and maintenance sys-
ems relevant to ageing as well the current knowledge on their fate
uring ageing and/or the eventual effects of their modulation on
geing and longevity.
. Protein modiﬁcation by carbohydrates
.1. Protein glycosylation
.1.1. Glycosylation: an overview
The term “glycan” refers to all forms of mono-, oligo-, or polysac-
haride, free or attached to another molecule, such as a protein or a
ipid (Varki et al., 2009). The most common types of glycans found
n eukaryotes are deﬁned based on the nature of their linkage to
he macromolecule. Glycoproteins are glycoconjugates in which a
rotein is covalently bound to one or more glycans. The binding
sually occurs via N or O linkages (Spiro, 2002).O-glycans (O-linked oligosaccharides) are mostly bindings
etween the polypeptide via a N-acetylgalactosamine (GalNAc) and
 OH-group of a serine or a threonine residue of the protein, and
an be extended into a variety of different structural core classes. and Development 151 (2015) 71–84
N-glycans (N-linked oligosaccharide) are sugar chains covalently
linked to asparagine residues of the protein, commonly involving
a N-acetylglucosamine (GlcNAc) residue and the consensus pep-
tide sequence: Asn-X-Ser/Thr (Varki et al., 2009). The focus in this
chapter will be on N-glycans.
It is important to emphasize that glycan chain structures are
not encoded directly in the genome and are secondary gene prod-
ucts. This is in contrast to protein (amino acid) sequences, which
are encoded by the genes and are inherited. Glycans are built by
glycosidases and glycosyltransferases, without an obvious encoded
template (Kamerling et al., 2007; Kondo et al., 2006). A small per-
centage of genes in the human genome are dedicated to produce
these enzymes and transporters responsible for the biosynthesis
and assembly of glycan chains, in the endoplasmic reticulum (ER)
and Golgi apparatus (Varki et al., 2009). The glycan chains them-
selves represent numerous combinatorial possibilities, generated
by a variety of competing and sequentially acting glycosidases and
glycosyltransferases (Lis and Sharon, 1993).
All N-glycans start with a common core sugar sequence,
(Man)3(GlcNAc)2-Asn-peptide and are classiﬁed into three types:
(1) “oligomannose”, in which only mannose residues are attached
to the core; (2) “complex”, in which “antennae” initiated by N-
acetylglucosaminyltransferases (GlcNAcTs) are attached to the
core; and (3) “hybrid”, in which only mannose residues are attached
to the Man1-6 arm of the core and one or two  antennae are on
the Man1-3 arm (Varki et al., 2009).
N-glycans are found on many secreted and membrane-bound
glycoproteins at Asn-X-Ser/Thr sequence. Analyses of protein
sequence databases have revealed that about two  thirds of the
entries contain the consensus Asn-X-Ser/Thr sequence. It is esti-
mated that at least two  thirds of those sequences are likely to be
N-glycosylated (von der Lieth et al., 2004). It is important to note
that whereas, the presence of the Asn-X-Ser/Thr sequence is neces-
sary for the receipt of an N-glycan, transfer of the N-glycan to this
sequence does not always occur, due to conformational or other
constraints during glycoprotein folding (Spiro, 2002).
Clearance of secreted glycoproteins can dependent on the com-
position of the glycan. Loss of sialic acid from glycoproteins triggers
clearance by the Kupffer cells, specialised liver macrophages which
carry receptors for asialoglycoproteins (Grifﬁths et al., 2014). The
mannose receptor is an endocytic receptor for glycans expressed
in a number of tissues, including the hepatic sinusoidal endothe-
lium. It was  shown that the mannose receptor is required for the
rapid clearance of a subset of mannose and GlcNac bearing serum
glycoproteins (Lee et al., 2002).
Along with glycosylation comes “microheterogeneity”. This
term indicates that at any given glycan attachment site on a certain
protein synthesized by a particular cell type, a range of variations
can be found in the structures of the attached glycan chain. The
extent of this microheterogeneity can vary considerable from one
glycosylation site to another, from glycoprotein to glycoprotein and
from cell type to cell type. Thus a given protein originally encoded
by a single gene can exist in numerous “glycoforms”, each effec-
tively a distinct molecular species (Varki et al., 2009).
Glycans can mediate a wide variety of biological roles by virtue
of their mass, shape, charge or other physical properties. We  refer to
the review of Ohtsubo and Marth (2006), for details on the functions
of glycans.
2.1.2. N-glycosylation proﬁling of serum proteins as marker of
physiological age
Small changes in the environment can cause dramatic changes
in glycans produced by a given cell therefore N-glycosylation can
be seen as a mirror of the status of the cell. For example, during liver
disease, hyperfucosylation, increased branching and bisecting Glc-
NAc are clearly observed on serum proteins (Blomme  et al., 2009)
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wig. 1. Rearrangements of the Amadori products.
he different rearrangements of the Amadori products are shown according to the ori
the  name which is still taken in nutrition science, nowadays in the biomedicine co
nd in rheumatoid arthritis patients a signiﬁcant increase in serum
lycans devoid of galactose and terminating in GlcNac is observed
Van Beneden et al., 2009). The major sources of N-glycosylated
roteins in serum are the B-cells (antibodies or immunoglobu-
ins: Ig) and the liver, but also macrophages (cytokines) and other
ell-types can contribute. Although many studies have shown the
mportance of structural changes of sugar chains of glycoproteins
uring development (Varki et al., 2009), limited data are avail-
ble on the changes in the sugar chains that take place during
geing.
Parekh et al. (1988) were the ﬁrst to investigate age-related N-
lycosylation changes on human serum IgGs. Healthy males and
emales varying in age from 1 to 70 years old were studied. The
elative incidence of agalactosyl (with both outer arms terminat-
ng in GlcNAc) N-glycans on total serum IgG decreased from birth
o a minimum (at 25 years of age) and then increased with age.
he relative incidence of digalactosyl structures varied inversely
o the amount of agalactyl N-glycans and the relative incidence
f monogalactosyl structures was constant. They concluded that
alactosylation of the N-glycans on the human serum IgGs of nor-
al  individuals is an age-related molecular parameter (Parekh
t al., 1988).
Ten years later a study similar to the one of Parekh et al. (1988)
as performed by Shikata et al. (1998) on human serum IgGs from
0 men  and women aged 18–73 years. The incidence of N-glycans
ith a bisecting GlcNAc increased with age in both male and femaleescription of Hodge in 1953 (Hodge, 1953) resulting in the formation of melanoidins
called advanced glycation endproducts, AGEs).
IgGs. It was  also shown that the level of agalactosyl N-glycans in
female IgG increases with age and that this change is caused by a
decrease in digalactosylated glycans but not monogalactosylated
glycans. A negative correlation between ageing and the incidence
of monosialo glycans in female IgG was  shown and this can be
attributed to a low level of galactosylation, which is essential for
sialylation of IgG glycans. In contrast, these age-related changes
were not so clear in male IgG samples. Therefore, it was  suggested
that the decrease in galactosylation of IgG oligosaccharides with
ageing is a female-speciﬁc phenomenon bearing in mind that the
size of the cohort is small.
More recently, 3 studies were performed using cohorts from
different European countries (study 1: Italian–Belgian subjects)
(Vanhooren et al., 2007); study 2: Dutch subjects (Ruhaak et al.,
2011); study 3: subjects from the Croatian Adriatic island of Vis
(Knezevic et al., 2009, 2010). These were reviewed in depth by
Dall’Olio et al. (2013). In these studies, not only serum Igs but
also the full serum glycoproteome was  analyzed. The general
observation among all three studies is that serum proteins have
reduced digalactosylated N-glycans and increased agalactosylated
N-glycans with increasing age although the human serum glycome
appears to be strongly inﬂuenced by genetic background. Therefore,
a large study with standardized isolation methods combining sub-
jects from different nationalities and genetic background is needed
to study in depth the role of N-glycosylation of serum proteins as
an ageing biomarker.
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.2. Protein glycation
.2.1. The Maillard reaction history
In 1912 the French chemist Louis-Maillard described a reaction
owadays known as the “Maillard reaction or browning reaction”
Maillard, 1912). He tried to explain the results of the interaction
f amino-acids with sugars at high temperature. But only more
han 40 years later in 1953 the Afro-American chemist John Edward
odge published the mechanism of the Maillard reaction (Hodge,
953). In 1979 the article published by Hodge in 1953 became a
Citation Classic” by the Science Citation Index giving Hodge pop-
larity among the carbohydrate chemists.
.2.2. Mechanism of the Maillard reaction
The Maillard or browning reaction is the result of the non-
nzymatic reaction of reduced sugars with the free amino group of
ucleic acids, lipids and proteins. In the article published by Hodge
1953), the Maillard reaction was summarized as the result of seven
ifferent types of reactions that occur during the browning (Fig. 1).
ccording to the three stage of development the reactions were
lassiﬁed:
I – Initial stage (colourless, no absorption in near UV)
A – Sugar-amine condensation
B – Amadori rearrangement
II – Intermediate stage (colourless or yellow, strong absorption
n near UV)
C – Sugar dehydration
D – Sugar fragmentation
E – Amino acid degradation
III – Final stage (highly coloured)
F – Aldol condensation
G – Aldehyde-amine polymerization; formation of heterocyclic
itrogen compounds
.2.3. Introduction to the term: advanced glycation end products
AGEs)
In a manuscript by Vlassara et al. in 1984 (Vlassara et al., 1984)
he Maillard reaction was described as follow: “Short-term incu-
ation of proteins with glucose results in the formation of ketoamine
Fig. 2. Formation of MGO, GO and 3-DG. MGO, G and Development 151 (2015) 71–84
adducts (Amadori product) with protein amino groups. These adducts
are reversible and reach equilibrium after several weeks. In addition
to detaching from the protein, these glyco-adducts can undergo very
slowly further rearrangements, dehydrations, and reactions to form
a number of advanced glycosylation end-products (AGE), which are
characteristically yellow-brown ﬂuorescent chromophores that can
cross-link proteins”.
This was  the birth of the term advanced glycosylation
end-products. However, in the same year the IUPAC–IUBMB (Inter-
national Union of Pure and Applied Chemistry–International Union
of Biochemistry and Molecular Biology) joint Commission on Bio-
chemical Nomenclature and the Nomenclature Commission of
IUBMB warned the improperly use of the terms glycosylated
hemoglobin, protein glycosylation, etc. to refer to the products of
the Maillard reaction. These compounds are not glycosides, but
result from the formation of a Schiff’s base followed by an Amadori
rearrangement. The term “glycation” for any reaction that links a
sugar to a protein, whether it is catalysed by an enzyme or not was
suggested. Thus glycation includes glycosylation as a special case.
However, commonly the term “advanced glycation end products”
refers to the products of the non-enzymatic Maillard reaction.
2.2.4. AGEs production
Outside of the body (exogenously) AGEs are formed during
the food preparation. Temperatures at 121 ◦C or higher accelerate
the reaction between sugars, protein and fat. Lower temperatures
with longer cooking time also favour the AGEs production. Thus,
foods like bread, roasted meat, French fries, etc., which during the
preparation are exposed to high temperatures, contain high AGEs-
levels. Among others detailed information about the AGEs-content
in some foods was  published by Goldberg et al. (2004), Uribarri
et al. (2010) and Hull et al. (2012). The endogenous AGE-production
(inside the body) is driven by the cellular metabolic processes.
Reactive oxoaldehydes (dicarbonyls) such as Methylglyoxal (MGO)
a spin-off product of the glycolysis (Fig. 2), Glyoxal (GO) formed
among others by lipid peroxidation and deoxyglucosone (3-DG)
formed after the decomposition of fructose 3-phosphate contribute
to AGE-generation (Table 1).
O and 3-DG are formed as a result of the glucose metabolism.
V. Vanhooren et al. / Mechanisms of Ageing and Development 151 (2015) 71–84 75
Table  1
Involvement of the three most prominent dicarbonyls in the AGEs formation with the corresponding AGE.
Dicarbonyl AGE Name
Glyoxal G-H1 Nd-(5-hydro-4-imidazolon-2-yl)ornithine
GOLD Glyoxal-derived lysine dimer
CML  Ne-carboxymethyl-lysine
Methylglyoxal MG-H1 Nd-(5-hydro-5-methyl-4-imidazolon-2-yl)-ornithine
MOLD methylglyoxal-derived lysine dimer
CEL  Ne-(1-carboxyethyl)lysine
Arg-pyr Arg-pyrimidine
THP Nd-(4-carboxy-4,6-dimethyl-5,6-dihydroxy-1,4,5,6-tetrahydro-pyrimidin-2-yl)-ornithine
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.2.5. Physical AGEs clearance
The knowledge about the disposability of ingested AGEs is
oor. In humans it was shown that about 3–10% of the con-
umed AGE (protein-bound fructose-lysine) is absorbed (Faist and
rbersdobler, 2001). Most recently the effect of Maillard reaction
roducts- (MRP) high and MRP-low diet on carboxymethyllysine
CML) intake and excretion in 11–14 years adolescent males was
tudied (Delgado-Andrade et al., 2012). The consumption of the
RP-high diet led to a higher CML  intake and absorption (11.28
s. 5.36 mg/day CML  for MRP-high and-low diet, respectively). In
arallel, the faecal excretion was also greater (3.52 vs. 1.23 mg/day
ML, respectively) and proportional to the dietary intake. The uri-
ary elimination of CML  was not increased signiﬁcantly when the
RP-high diet was consumed compared to consumption of the
RP-low diet, and was not proportional to the dietary exposure
f CML. The authors concluded that CML  absorption and faecal
xcretion were highly inﬂuenced by dietary CML  levels. The dis-
ordance between the CML  intake and the CML  amount found in
he faecal excretion suggested that most of the ingested CML  had
n unknown destination in the body. Once in the gastrointestinal
ract, the microbial activity will degrade a portion of AGEs and the
est could be absorbed or eliminated. A portion of the absorbed
GEs will reach the circulation intact and will be transported to
ifferent tissues/organs were metabolism can occur (Somoza et al.,
006).
.2.6. AGEs biological activity
A vast amount of accumulated data ascribed AGEs a negative
hysiological role in the progress and complication of diseases
uch as diabetes mellitus, renal dysfunction, age-related neurode-
enerative disorders (Alzheimer’s, Parkinson’s, and Huntington’s
iseases), cardiovascular diseases and many others (Sun et al.,
013; Chilelli et al., 2013; Nishizawa et al., 2012; Beisswenger et al.,
013; Fawver et al., 2012; Guerrero et al., 2013; Li et al., 2012;
imm,  2013). AGEs play a particular role in the process of arte-
ial ageing (stiffness). In large arteries, a feature of ageing is the
ecreased turnover of collagen and elastin and the increased AGEs
nd cross-links. The lysis and disorganization of the elastic ﬁbers
s accompanied by their replacement by collagen and other matrix
omponents. These events cause the loss of elasticity and induce
tiffening (Sell and Monnier, 2012). A positive effect was observed
y the use of aminoguanidine (blocker of the Maillard reaction) by
educing AGEs accumulation in tissues in experimental diabetes
Thomas et al., 2005). In other study aminoguanidine prevented the
ge-related increase in cardiac hypertrophy and arterial stiffening
Cantini et al., 2001). As for aminoguanidine side effects associ-
ted with its chronic administration during a human trial which
ncluded vasculitis and abnormalities in liver function was reported
Montagnani, 2008), its use in human is difﬁcult (Sell and Monnier,
012). Another group of compounds, the so called “AGEs and cross-
inks breakers” has been developed. The most studied is alagebriumazolones derived from 3-deoxyglucosone
cosone-derived lysine dimer
(Sell and Monnier, 2012). However in a recent study the application
of alagebrium to improve the excercise capacity and cardiac func-
tion in patients with systolic hear failure did not show any beneﬁt
(Hartog et al., 2011).
The cellular AGEs-action is mediated by receptors on the cell
surface. At least six AGE-receptors are known and their expression
is cell/tissue-type dependent (Table 2). The multi-ligand receptor
for advanced glycation end products (RAGE) is the most studied
AGE-receptor. Among the receptor’s ligands are AGEs, amyloid ˇ
peptide; S100/calgranulin protein, high mobility group box 1 pro-
tein (HMGB1) and lipopolysaccharide (LPS) (Rojas et al., 2013). By
binding to the receptor these molecules can activate a series of
signal pathways (Ott et al., 2014). In renal epithelial LLC-PKl cells,
AGE-BSA stimulates the p42MAP kinase as well as the transcrip-
tion factor AP1 and inhibits cell proliferation (Simm et al., 1997).
AGE–RAGE interaction induces NADPH-oxidase activity, resulting
in activation of Nf-B and increased iNOS expression in rat vascular
smooth muscle cells (San Martin et al., 2007). In human aor-
tic smooth muscle cells, AGE–RAGE interaction activates alkaline
phosphatase and thereby vascular calciﬁcation via the p38MAPK
pathway (Tanikawa et al., 2009). In rat cardiac ﬁbroblasts, AGE–BSA
induces activation of ERK and p38-MAP kinases followd by NF-
B and ATF-2 transcription factor activation and expression of
metalloproteinases MMP-2, MMP-9 and MMP-13 (Daoud et al.,
2001). In the macrophage RAW cell line, AGEs stimulates Jak-2
and Stat-1 phosphorylation via RAGE and modify downstream the
composition and activity of subunits of the immunoproteasome
(Grimm et al., 2012). In human chondrocytes, AGE-RAGE interac-
tion mediates inﬂammatory responses via JNK kinase, p38 MAP
kinase, ERK, and NF-B (Nah et al., 2008). In H9C2 cells (rat car-
diac myoﬁbroblasts) AGEs induces intracellular ROS production
and the expression of inﬂammatory cytokines like TNF- (Umadevi
et al., 2013). In summary, in many cell types, AGEs modiﬁed pro-
teins induces intracellular ROS, NF-B induction resulting in the
secretion of inﬂammatory cytokines (Fig. 3). In turn, the secretion
of these molecules can yield to unwanted negative reactions (cell
migration, cell activation, inﬂammatory response) resulting in cell
and tissue damage.
2.2.7. Methods for AGEs determination
As ﬂuorescent compounds AGEs can be measured by registe-
ring the AGEs-ﬂuorescence. However, not all AGEs are ﬂuorescent
molecules or there exist molecules with the same range of ﬂuo-
rescence but are not AGEs. To the AGEs-ﬂuorescent compounds
belongs pentosidine, a ribose metabolite. One of the most studied
AGE, carboxymethyllysine (CML) does not ﬂuoresce. Regarding the
ﬂuorescence, AGEs were well characterized by Schmitt et al. (2005).
Three different ranges of AGE-ﬂuorescence were established (exci-
tation/emission: 330/395, 365/440, 485/530 nm). Complementary
the ﬂuorescence of glycated tryptophan can be measured at an
excitation of 280 nm and an emission of 350 nm.
76 V. Vanhooren et al. / Mechanisms of Ageing and Development 151 (2015) 71–84
Table 2
AGE-receptors (based on the review article of Ott et al., 2014).
AGE-receptors Cell types Ligands Function
RAGE Monocytes, macrophages, T-lymphocytes,
endothelial cells, mesangial cells, ﬁbroblasts,
smooth muscle cells, neuronal cells
S100 proteins, HMGB-1, -amyloid, -integrin
Mac-1, AGEs
Endocytosis, signaling
AGR-R1/OST-48/p60 Monocytes, macrophages, T-lymphocytes,
endothelial cells, mesangial cells, ﬁbroblasts,
smooth muscle cells, neuronal cells
Endocytic uptake and degradation of
AGE-modiﬁed proteins, protective
against oxidative stress
AGR-R2/80K-H/p90 Monocytes, macrophages, T-lymphocytes,
endothelial cells, mesangial cells, ﬁbroblasts,
smooth muscle cells, neuronal cells
AGEs Signaling, regulatory subunit of
glucosidase II
AGE-R3/galectin-3 Monocytes, macrophages, T-lymphocytes,
endothelial cells, mesangial cells, ﬁbroblasts,
smooth muscle cells, neuronal cells
IgE receptor, colon cancer mucin, CD66, LPS,
Mac-1, Mac-3, LAMPs (1,2), AGEs, IgE, laminin,
tenascin, ﬁbronectin,collagen IV, gp90/Mac-2
binding protein
Signaling
SR-A (I/II) Monocytes, macrophages, dendritic cells,
endothelial cells
AcLDL, OxLDL, AGEs, -amyloid, pathogen
recognition
Endocytic uptake and degradation of
modiﬁed LDL and AGE-modiﬁed
proteins
SR-B/CD36 Platelets, endothelial cells, epithelial cells,
adipocytes, B-lymphocytes
AcLDL, OxLDL, HDL, LDL, VLDL, collagen,
thrombospondin, long chain fatty acids,
maleylated BSA, anionic phospholipids, AGE,
apoptotic cells, pathogen recognition
Endocytic uptake and degradation of
AGE-modiﬁed proteins, cell adhesion,
regulator of fatty acid transport
SR-BI  Tissues which are active in selective uptake of
HDL (liver, steroidogenic)
AcLDL, OxLDL, HDL, LDL, VLDL, maleylated BSA,
anionic phospholipids, AGEs
Selective uptake of HDL, Endocytic
uptake and degradation of AGEs
SR-E/LOX-1 Endothelial cells, macrophages, smooth muscle
cells
OxLDL, Hsp70, apoptotic cells, activated
platelets, p
Endocytic uptake and degradation of
FEEL-1/FEEL-2 Endothelial cells, monocytes/macrophages AcLDL, AG
recognitio
Fig. 3. Simpliﬁed RAGE signaling pathways.
The binding of the RAGE ligands to the receptor leads to the activation of different
signaling cascades. In addition activated RAGE induces the generation of ROS. As
a  result of the activation nuclear transcription factors (NF-B and others) translo-
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has been found in most human tissues such as glands, kidney, pla-ate to the nucleus inducing among others the gene expression of inﬂammatory
ytokines.
Other possibility to detect AGEs is the use of speciﬁc antibod-
es (ELISA, Western blot). However, the existence of commercially
vailable antibodies for all of the known AGEs is limited. On the
ther hand this is one of the reasons why CML  has been so well
haracterized in cells and tissues.
Although expensive, the most sensitive and accurate method
or the AGEs-analysis is the liquid chromatography–mass spec-
rometry with tandem mass spectrometry (LC–MS/MS). Using this
pproach Thornalley et al. (2003) absolutely quantiﬁed AGEs in
uman plasma and urine and further found that AGEs content inathogen recognition modiﬁed oxLDL, signaling
E, SPARC, hyaluronic acid, pathogen
n
Endocytic uptake and degradation of
AGEs hyaluronic acid and AcLDL
cellular proteins was  higher than in plasma protein (Thornalley
et al., 2003).
2.2.8. AGEs as biomarker
As AGEs accumulate during ageing their quantitation could be
a good biomarker of age. With the development of the AGE-reader
(DiagnOptics B.V., Groningen, The Netherlands) the measurement
of the AGEs (their tissue accumulation) in the skin by mean of
the skin autoﬂuorescence (skin AF; sAF) is possible. We and oth-
ers could show that indeed AGEs well correlate with the age and
can be used as an age-biomarker (Simm et al., 2008). In addition,
in the clinical routine, the percentage of glycated hemoglobin is
widely used as biomarker in the diabetes mellitus diagnosis.
As a non-invasive method for the quantitation of AGEs, the AGE-
reader actually ﬁnds an increasing propagation in the diagnosis and
assessment of disease’s complications. The below referred publica-
tions are only a short selection of recently published data on the
very rapidly increasing ﬁeld “Quantitative-AGEs” as a biomarker of
age and diseases (Hofmann et al., 2013; Mulder et al., 2006; Mac-
Way  et al., 2014; Smit et al., 2013; Arsov et al., 2013).
3. Protein maintenance
3.1. Clusterin/Apolipoprotein J
3.1.1. Clusterin/Apolipoprotein J: an overview
Clusterin/Apolipoprotein J (CLU) gene encodes for two  pro-
tein isoforms; a highly conserved disulﬁde-linked heterodimeric
secreted glycoprotein of ∼75–80 kDa (sCLU) (de Silva et al., 1990a;
Wong et al., 1994) was  ﬁrstly identiﬁed in ram rete testis ﬂuid
(Blaschuk et al., 1983) and a truncated nuclear form (nCLU) (Leskov
et al., 2003) was reported in human and murine cell lines exposed
to various stress inducers (e.g. radiations, heat shock, drugs, etc.) as
well as in carcinoma cells (Bettuzzi and Rizzi, 2009; Bhutia et al.,
2012; Caccamo et al., 2003; Shannan et al., 2007, 2006). The sCLUcenta, liver, lymphoid tissues, epithelia, red blood cells and platelet
alpha-granules (Antonelou et al., 2011 Aronow et al., 1993; de Silva
et al., 1990a; Ekici et al., 2008; Gnatenko et al., 2003; Itahana et al.,
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007; Shin et al., 2008; Verbrugghe et al., 2008). It is a major pro-
ein in the serum and in most of the physiological ﬂuids including
erebrospinal ﬂuid, eye’s aqueous, milk, urine and semen (Blaschuk
t al., 1983; de Silva et al., 1990b; Dota et al., 1999; Jenne and
schopp, 1989; Kapron et al., 1997; Kirszbaum et al., 1989; Nilselid
t al., 2006). sCLU serves as apolipoprotein through its associa-
ion with high-density lipoprotein (HDL) particles (de Silva et al.,
990a), dictating an important role in lipid metabolism and trans-
ort (Jenne et al., 1991; Kujiraoka et al., 2006). In addition sCLU
lso protects, in an ATP-independent manner, from protein aggre-
ation and precipitation via its binding to hydrophobic regions of
isfolding-prone proteins (Poon et al., 2000). Recently, sCLU has
een classiﬁed as a functional homologue of the small heat shock
roteins (Wyatt et al., 2009; Wyatt et al., 2011) due to its chap-
rone activity (Lakins et al., 2002; Materia et al., 2011; Narayan
t al., 2012; Zoubeidi et al., 2010). With regards to its chaperone
roperty sCLU is implicated in numerous physiological processes
ncluding development (Aronow et al., 1993), lipid transportation
de Silva et al., 1990b), differentiation (Trougakos et al., 2006), cel-
ular senescence, in vivo ageing as well as in many age-related
iseases including neurodegeneration (Charnay et al., 2012), vas-
ular damage, diabetes and tumorigenesis (Trougakos and Gonos,
006).
In clinical cancer research, clusterin has been established as a
ey therapeutic target as it has been found upregulated in various
uman malignancies promoting tumor growth, metastatic progres-
ion, cell survival to chemotherapy and ionizing radiation therapy
Criswell et al., 2003; Gleave and Jansen, 2003; Trougakos and
onos, 2002).
.1.2. CLU association with stress and ageing
The impact of CLU on the regulation of ageing and stress
esponse is highlighted not only by its induction in many patholog-
cal and age-related conditions including atherosclerosis, kidney
egenerative diseases, carcinogenesis and several neurodegener-
tive disorders such as Scrapie, Alzheimer disease, epileptic foci
nd Pick’s disease under increased oxidative stress and injury
Calero et al., 2000; Koch-Brandt and Morgans, 1996; Rosenberg
nd Silkensen, 1995) but also by its extracellular chaperone activ-
ty (Humphreys et al., 1999). CLU can interact with a few misfolded
roteins in order to keep them soluble until the bound protein
an be re-folded or degraded (Dabbs and Wilson, 2014; Wyatt
t al., 2011). In vivo, complexes that were constructed between
LU and misfolded proteins in a rat model, were quickly cleared
y hepatocytes and were degraded within lysosomes via receptor-
ediated endocytosis by scavenger receptors (Wyatt et al., 2011).
t has been suggested that CLU plays a key role in extracellular pro-
eostasis because it is a member of extracellular chaperones that
articipate in the clearance of extracellular body ﬂuids from mis-
olded proteins, inhibit them from forming toxic aggregates (Wyatt
t al., 2013). Considering also that oxidants and oxidation injury
odulate the activity of both the Activator Protein-1 (AP-1) and
eat-shock transcription factor 1 (HSF1) (Martindale and Holbrook,
002), the combined presence of both the AP-1 and “CLU-speciﬁc
lement” (CLE) regulatory elements in the CLU gene promoter (Jin
nd Howe, 1997; Michel et al., 1995) make CLU gene an extremely
ensitive biosensor to environmental changes and particularly to
he direct or indirect downstream effects of free radicals and their
erivatives.
Recently, Riwanto et al. (2013) reported a higher prevalence
f sCLU, a component of HDL, in healthy subjects compared to
atients with coronary artery disease suggesting a protective role
f sCLU in vascular disease progression (Riwanto et al., 2013). In
ine with these ﬁndings, reduced level of sCLU in high-density
ipoproteins (HDL) has been correlated with increased insulin resis-
ance, diabetes and obesity (Hoofnagle et al., 2010), while clusterin and Development 151 (2015) 71–84 77
gene polymorphism was recently linked to type 2 diabetes melli-
tus (Daimon et al., 2011). Previous study had also shown that serum
clusterin level increases signiﬁcantly in diabetic type II patients and
in patients with developing coronary heart disease or myocardial
infarction (Trougakos et al., 2002).
During in vivo ageing CLU gene expression is signiﬁcantly ele-
vated from gestation to adults in humans (Mondello et al., 1999;
Wong et al., 1994) whereas in ﬁbroblast samples derived from
donors of different ages, including centenarians, CLU expression
was not positively correlated with donor age (Mondello et al.,
1999). However, high levels of plasma clusterin were recently
reported in healthy “supernormal” centenarians (older than 105
years), indicating a possible role of this protein in longevity (Miura
et al., 2011; Shiota et al., 2011). Furthermore, various studies sup-
port a major impact of sCLU in the pathogenesis of Alzheimer
disease (AD) revealing that allele variants of CLU are associated
with increased risk of AD (Harold et al., 2009; Lambert et al., 2009)
Finally, sCLU, among other apolipoproteins, has been identiﬁed as a
potential plasma biomarker of cognitive decline in non-demented
elderly individuals (Song et al., 2012). To conclude, the diverse func-
tions of CLU and its pivotal action in the regulation of life expectancy
and progression of age-related diseases emerge CLU as an excellent
biomarker of cellular senescence and organismal ageing.
3.2. Proteasome
Protein homeostasis plays an important role for preserving
biological integrity and ﬁtness both at the cellular, tissular and
organismal levels. The lysosomal and proteasomal pathways are
the two  main proteolytic machineries by which intracellular
proteins are degraded. However, the proteasome is the main pro-
teolytic system implicated in the turnover of cellular proteins
through the targeted degradation of poly-ubiquitinated proteins as
well as the removal of altered proteins. Impairment of proteasome
function has been associated with ageing in a variety of mammalian
tissues and cell types, hence contributing to the age-related accu-
mulation of oxidatively proteins due to their decreased elimination.
This chapter summarizes the most relevant features of the protea-
somal system and the current knowledge on the impact of ageing
on proteasome structure and function mostly in mammals but also
on the modulation of proteasome activity and its effect on ageing
and longevity.
3.2.1. 20S and 26 proteasome structure and function
The 20S proteasome is a high molecular weight multicatalytic
proteolytic complex found in Archae and Eukaryotes (Coux et al.,
1996; Voges et al., 1999). In mammalian cells, in which it can rep-
resent up 1% of total proteins (Tanaka et al., 1986), the proteasome
constitutes the main non lysosomal proteolytic system involved
in protein degradation in the cytosol and in the nucleus. Besides
acting as a housekeeping enzyme by eliminating abnormal and oxi-
dized proteins (Davies, 2001; Grune et al., 1997), the proteasome
is also implicated in a broad range of cellular functions through
the selective degradation of ubiquitin-targeted regulatory proteins
such as transcription factors, cyclins and rate-limiting enzymes
in important metabolic pathways (Ciechanover and Iwai, 2004;
Goldberg et al., 1997; King et al., 1996). The 20S proteasome is
made up of four stacked rings of seven subunits classiﬁed as 
or  subunits (Groll et al., 1997; Hegerl et al., 1991; Lowe et al.,
1995). The eukaryotic proteasome carries three catalytically active
 subunits : 1 for the peptidyl glutamylpeptide hydrolase (or
caspase-like) activity, 2 for the trypsin-like activity and 5 for the
chymotrypsin-like activity that cleave peptide bonds after an acidic,
basic and hydrophobic aminoacid, respectively (Coux et al., 1996;
Groll et al., 1997; Kisselev et al., 1999). When cells are exposed to
such stimuli as IFN, TNF or LPS the subunit composition of the
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0S proteasome is modiﬁed, as inducible homologous subunits are
ncorporated in the structure upon de novo synthesis: the i1, i2
nd i5 subunits, respectively replace their 1, 2 and 5 consti-
utive counterparts to form the immunoproteasome (Fruh et al.,
994; Gaczynska et al., 1993; Tanaka, 1994). Such replacement of
roteasome subunits modify proteasome peptidase activities and
ead to higher chymotrypsin-like and trypsin-like activities and
ower peptidyl glutamylpeptide hydrolase activity, thus increasing
roduction of peptides with higher afﬁnity for MHC  class I com-
lex (Fruh et al., 1994; Gaczynska et al., 1993; Tanaka, 1994). In
ddition, the immunoproteasome has also been implicated in adap-
ation to oxidative stress by degrading oxidized proteins (Pickering
t al., 2010), in longevity (Rodriguez et al., 2012) and in ageing
s a response to chronic inﬂammation (Ferrington and Gregerson,
012).
The 26S proteasome results from the ATP-dependent asso-
iation with the PA700 or 19S regulator and is an essential
omponent of the ubiquitin-proteasome degradation pathway of
oly-ubiquitinated proteins. The association of PA28 or 11S reg-
lator to the 20S proteasome is ATP-independent and results in
n increase of proteasome peptidase activities while it does not
mprove protein degradation (Dubiel et al., 1992; Ma  et al., 1992;
hitby et al., 2000). As for the immunoproteasome subunits, the
xpression of PA28 subunits is induced after treatment of cell by
nterferon . In the cytosol PA28 is composed of two  types of sub-
nits  and  of about 28 kDa forming heptameric rings while in
he nucleus PA28 is made of single type subunit  (Knowlton et al.,
997; Mott et al., 1994). The 19S regulator is composed of eigthteen
ubunits belonging to either the « lid » or the « base » of the com-
lex. Six of the nine subunits of the base are ATPases exhibiting a
haperone-like activity (Hershko and Ciechanover, 1998; Hershko
nd Ciechanover, 1998). The lid subunits are involved in the recog-
ition of polyubiquitinated protein substrates and recycling the
biquitin moiety through isopeptidase activity (Deveraux et al.,
994; Hershko and Ciechanover, 1998).
.2.2. Age-related impairment of proteasome function
Damage to macromolecules has been implicated in the cellular
egeneration that occurs during ageing and accumulation of oxi-
ized proteins represents a hallmark of cellular ageing (Beckman
nd Ames, 1998; Stadtman, 2006). Elimination of damaged pro-
ein and protein turnover is critical to preserve cell function and
he main proteolytic system in charge of cytosolic protein degra-
ation is the proteasome (Coux et al., 1996; Davies, 2001; Grune
t al., 1997; Voges et al., 1999). Since accumulation of oxida-
ively damaged protein with age can be due to increased protein
lteration, decreased elimination (i.e.  repair and degradation) of
amaged protein or the combination of both phenomenoms, one
f the hypothesis that has been put forward to explain oxidized pro-
ein build-up is a decrease of proteasome activity with age (Friguet,
006; Baraibar and Friguet, 2012).
During the past recent years several lines of evidence have
ndicated that proteasome function is impaired during the ageing
rocess suggesting that this decreased activity might be causally
elated to ageing and age-associated diseases (Friguet, 2002;
reusing and Grune, 2008; Davies, 2001; Shringarpure and Davies,
002), although some studies have shown that this decline may  not
e universal (Altun et al., 2010; Cook et al., 2009). Pioneering studies
rom our group and that of Walter Ward indicated that proteasome
roteolytic activity is compromised with ageing (Conconi et al.,
996; Shibatani et al., 1996; Shibatani and Ward, 1996). A decrease
n proteasome peptidase activity has been reported in aged tissues
f other mammals (mouse, rat and bovine), like liver (Conconi et al.,
996; Shibatani et al., 1996; Shibatani and Ward, 1996; Hayashi
nd Goto, 1998), spinal cord (Keller et al., 2000), lens (Shang et al.,
001), heart (Bulteau et al., 2002) and retina (Louie et al., 2002). Fur- and Development 151 (2015) 71–84
thermore, an age-related decline of proteasome activity has been
also shown ex vivo in human lymphocytes (Ponnappan et al., 1999;
Carrard et al., 2003), keratinocytes and ﬁbroblasts (Petropoulos
et al., 2000; Bulteau et al., 2000) and in human primary cell cul-
tures undergoing replicative senescence (Merker and Grune, 2000;
Sitte et al., 2000a,b; Chondrogianni et al., 2003). Impairment of pro-
teasomal activity has also been reported during ageing in model
organisms such as Drosophila melanogaster (Vernace et al., 2007;
Tonoki et al., 2009) and Caenorhabditis elegans (Hamer et al., 2010).
In contrast, centenarians who represent an interesting example of
successful ageing, and the long-lived naked mole rats were found
to exhibit elevated proteasome levels and activity (Chondrogianni
et al., 2000; Perez et al., 2009).
In addition, recent studies have shown that the proteasome can
be activated by genetic manipulations as well as by factors that
affect either its conformation and stability or the expression of
its subunits and the rate of proteasome assembly (Bulteau et al.,
2006; Katsiki et al., 2007; Chondrogianni et al., 2014b). Indeed,
over-expression of the 20S 5 subunit extended the replicative
lifespan of cultured human ﬁbroblasts (Chondrogianni et al., 2005).
Interestingly, the restoration of normal level of proteasome activity
upon lentiviral transfection of proteasome catalytic subunits was
found to reduce ageing markers in dermal ﬁbroblasts from elderly
persons (Hwang et al., 2007). Concerning model organisms, over-
expression of 19S proteasome activator subunit Rpn11 prolonged
D. melanogaster lifespan (Tonoki et al., 2009), overexpression of the
proteasome related transcription factor Rpn4 enhanced the replica-
tive lifespan and resistance to proteotoxic stress of Saccharomyces
cerevisiae (Kruegel et al., 2011; Yao et al., 2015), while overex-
pression of the 19S proteasome activator subunit rpn-6 and of
the pbs-5 proteasome catalytic subunit also led to an extension
of lifespan and resistance to proteotoxic stress (Vilchez et al., 2012;
Chondrogianni et al., 2015)
3.3. Methionine sulfoxide reductase, an oxidized protein repair
system
Most of the altered proteins are eliminated through degradation
and very few repair systems relevant to protein oxidative damage
have been documented. Indeed, only certain oxidation products of
the sulfur-containing amino acids cysteine and methionine can be
reversed back to their reduced forms within proteins (Petropoulos
and Friguet, 2006; Chondrogianni et al., 2014a). The systems that
have been implicated in reversing the oxidation of disulﬁde bridges
and sulfenic acid, include the reduced forms of small proteins such
as thioredoxin and glutaredoxin that get oxidized and are further
recycled back to their reduced forms by thioredoxin reductase
and glutathione/glutathione reductase, respectively. Conversely,
methionine sulfoxide can be enzymatically reduced within pro-
teins by the methionine sulfoxide reductase system that is further
described below.
3.3.1. Oxidized protein repair by the methionine sulfoxide
reductases
Methionine sulfoxide reductases (Msr) are oxidoreductase
enzymes that catalyze the reduction of methionine sulfoxide back
to the reduced form of methionine within proteins. Oxidation of
methionine most often lead to an impairment of protein func-
tion while reduction of methionine sulfoxide has been associated
with its recovery. Thus, oxidation/reduction of methionine has
been implicated in redox regulation of both protein function and
protein-protein interaction (Moskovitz, 2005; Petropoulos and
Friguet, 2006). It has also been proposed that Msr  enzymes can act
as effective antioxidant by scavenging ROS (Levine et al., 1996).
Surface-exposed methionyl residues can be easily oxidized by
almost all kinds of ROS and then further reduced by Msr  through
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uccessive oxidation/reduction reactions that are trapping ROS
nd preventing further protein irreversible oxidative modiﬁcations
Picot et al., 2005; Cabreiro et al., 2008). Hence, in the presence of
ctive Msr  surface-exposed methionyl residues appears as built-in
rotein antioxidants.
Methionine oxidation results in the formation of two
iastereoisomers of methionine sulfoxide, Met-S(O) and Met-R(O),
hich can be further oxidized into methionine sulfone which is
n irreversible oxidative modiﬁcation. The two diastereoisomers of
ethionine sulfoxide, Met-S(O) and Met-R(O), are reduced back to
ethionine by Msr  A and MsrB, respectively, that are then reduced
y the thioredoxin/thioredoxine reductase system.
Msr  genes are found in almost all organisms from bacteria to
ammals (Delaye et al., 2007; Kryukov and Gladyshev, 2002).
n mammals, one gene is coding for MsrA which exhibits differ-
nt isoforms that are present both in the cytosol, in the nucleus
nd the mitochondrial matrix (Hansel et al., 2002; Vougier et al.,
003). In contrast, three distinct genes are encoding the differ-
nt forms of MsrB in mammals. MsrB1, a selenoprotein, is present
oth in the nucleus and the cytosol while MsrB2 is present in the
itochondria. MsrB3 is localized in the endoplasmic reticulum and
he mitochondria (Hansel et al., 2005; Kim and Gladyshev, 2004).
ll three MsrB are present in mammalian tissues, although at dif-
erent levels (Hansel et al., 2005). Human MsrA mRNA was detected
n all human tissues with highly varying expression levels. The
aximum expression was found in kidney, cerebellum followed by
iver, heart, bone marrow and hippocampus (Kuschel et al., 1999).
nterestingly, FOXO3a was found to directly activate the human
srA promoter in a cell culture system, suggesting that this could
e a conserved mechanism for MsrA regulation (Minniti et al.,
009). Although not present in certain leukemia cell lines, MsrA
s expressed in peripheral blood lymphocytes (PBL), the highest
xpression being observed in the neutrophil granulocytes (Achilli
t al., 2008).
.3.2. Implication of Msr  in resistance to oxidative stress, ageing
nd longevity
Accumulation of damaged proteins has been proposed to play
 crucial role in ageing and the expression of various age-related
iseases (Stadtman, 2006) while failure of protein maintenance, i.
. degradation and repair, has been implicated in the age-related
ccumulation of damaged protein (Friguet, 2006; Petropoulos and
riguet, 2006). Hence, resistance to oxidative stress, decreased pro-
ein damage and improved protein maintenance are believed to be
ey elements for determining the lifespan and the rate of ageing of
rganisms.
The oxidized protein repair system Msr  has been implicated in
oth cellular protection against oxidative stress and protein oxida-
ive damage. Most of the evidence is coming from overexpression
f either MsrA or MsrB in different eukaryotic cellular and organ-
smal models ranking from yeast to D. melanogaster. Knock-out
ellular and organismal models for Msr  including C. elegans and
ice, have also been the subject of studies addressing the role of
sr  in resistance against oxidative stress and in longevity. In addi-
ion, the Msr  system was shown to decline with age and has been
ecently associated with a number of human diseases (ref). Inter-
stingly, age-related increase of methionine sulfoxide content has
een documented in rat brain calmodulin and human skin collagen
Michaelis et al., 1996; Wells-Knecht et al., 1997).
We have ﬁrst reported that MsrA expression is reduced dur-
ng ageing in rat organs, i.e.  liver, kidney and brain (Petropoulos
t al., 2001). Conversely, MsrB1, but not MsrA activity, was reduced
ith age in mouse liver, suggesting that MsrB1 may  account for
he impaired methionine sulfoxide reduction in ageing mice liver
Novoselov et al., 2010). Moreover, both MsrA and MsrB2 expres-
ion were decreased exhibited a decrease in upon replicative and Development 151 (2015) 71–84 79
senescence of WI-38 human ﬁbroblasts which was concomitant
with a decline of total Msr  activity (Picot et al., 2004). Further stud-
ies have revealed that the decrease in Msr  activity upon replicative
senescence is more important in the mitochondria than in the cyto-
sol (Ahmed et al., 2010). This decline of oxidized protein repair has
been suggested to contribute to the age-associated accumulation
of oxidatively damaged proteins.
Overexpression of MsrA predominantly in the nervous system
of D. melanogaster resulted in a 70% increase in median survival
and was shown to increase resistance to paraquat-induced oxida-
tive stress (Ruan et al., 2002). However, ubiquitous overexpression
of Drosophila MsrB or mouse MsrB1 or MsrB2 did not change the
lifespan and oxidative stress resistance while ectopic expression
of mouse MsrB1 in the nervous system led to an increased resis-
tance against oxidative stress, but did not affect lifespan, revealing
different effects of MsrA or MsrB on Drosophila ageing (Shchedrina
et al., 2011; Shchedrina et al., 2009). In addition, both neuronal and
ubiquitous expression of hMsrB3A rendered Drosophila resistant to
oxidative stress and signiﬁcantly extended their lifespan (Lim et al.,
2012). It was initially reported that MsrA knock-out mice had a 40%
reduced lifespan (Moskovitz et al., 2001) but more recent ﬁndings
have shown that the lack of MsrA has no effect on mouse longevity
when hosted in a proper environment in which wild-type lifespan
was also increased as compared to the one observed in the previ-
ous study (Salmon et al., 2009). Nevertheless, MsrA knock-out mice
were more sensitive to oxidative stress (Salmon et al., 2009) and
presented a higher level of protein carbonyls than the wild type
when exposed to hyperoxia (Moskovitz, 2007).
4. Conclusion
As described above, the candidate ageing biomarkers analysed
within the workpackage dedicated to “markers based on proteins
and their modiﬁcations” are focusing on enzymatic and non-
enzymatic post-translational modiﬁcations of serum proteins by
carbohydrates and on intracellular protein maintenance systems
that are involved either in chaperoning or in the removal of oxida-
tively damaged proteins through degradation and repair. Indeed,
changes in the abundance and post-translational modiﬁcation of
proteins and accumulation of modiﬁed proteins have been pro-
posed to represent hallmarks of biological ageing while protein
maintenance failure has been recognized as a major contributor
to the age-associated accumulation of damaged proteins, includ-
ing oxidized proteins that are analysed within the workpackage
dedicated to “oxidative stress markers”. Thus, the markers based on
proteins and their modiﬁcations represent a unique set of potential
biomarkers to be further combined with the other biomarkers that
will emerge from the complementary groups of classic and/or new
markers reported in the other workpackages: “DNA-based mark-
ers”, “oxidative stress markers”, “clinical chemistry, hormones and
markers of metabolism” and “immunological markers”. Indeed, it
is expected that a combination of several biomarkers will provide
a much better tool to measure biological age than any single
biomarker in isolation. This combination is also aimed at optimis-
ing the weighting of the different markers since it is expected that
not all biomarkers are of equal weight and just averageing all of
them is most likely to be not appropriate.
For the most part, the markers based on proteins and their
modiﬁcations that have been chosen are directly related with
mechanistic aspects of the ageing process. Indeed, they are rel-
evant to such important physiological features such as protein
homeostasis and glycoprotein secretion that have been previously
documented as being altered with age. Therefore, it is expected that
they may  be less inﬂuenced by other factors not necessarily related
with ageing. Hence, The research tasks that have been speciﬁcally
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ddressed within the frame of the “markers based on proteins and
heir modiﬁcations” include: (1) the analysis of the N-glycomic
hanges in glycoproteins from donors blood, the urine glycopro-
ein changes being also studied in a subset of subjects, in Ghent,
elgium; (2) the monitoring of AGEs in plasma by ﬂuorescence
pectroscopy and by immunological analysis of speciﬁc AGEs such
s carboxy-methyllysine, pentosidine, Arg-pyrimidine and imida-
olone, in Halle, Germany; (3) the measurements of ApoJ/CLU levels
n donors serum in Athens, Greece; (4) the measurements of protea-
ome and methionine sulfoxide reductase activities and the protein
evels in donors PBMC lysates in Paris, France. These tasks have been
chieved using biological samples (blood and urine) collected from
he two recruited large groups of subjects from different European
ountries described earlier and referred as to: RASIG (for randomly
ecruited age-stratiﬁed individuals from the general population)
nd GEHA offspring (for subjects born from a long-living parent
elonging to a family with long living sibling(s) already recruited
n the framework of the GEHA project) and their spouses as controls.
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